You are hereMay 1, 2018
What’s the Stem Cells Buzz this Week? - Cardiomyocyte Maturation, CPCs and ECM, In Vitro effects on Hematopoietic Cells, and AICLI Stem Cell Trial Results!
The Stem Cells Portal brings you a roundup of some of the new and exciting stories in the ever-changing world of stem cells, regenerative medicine, and beyond!
Cardiomyocyte Maturation requires TLR3 activated NFκB
A new study from the labs of Conrad P. Hodgkinson and Victor J. Dzau (Duke University, Durham, North California, USA) recently set out to understand the processes leading to the production of cardiomyocytes. Hodgkinson et al. discovered that the maturation of committed precursors into mature cardiomyocytes requires the activity of the TLR3‐NFκB pathway. For more details, make your way over to STEM CELLS now!
CPCs and the Extracellular Matrix
A new Perspective article from Clotilde Castaldo (University of Naples “Federico II”, Naples, Italy) and Isotta Chimenti (“La Sapienza” University of Rome, Italy) asks us to consider the importance of the extracellular matrix (ECM) when proposing novel regenerative therapies for heart failure. To this end, the authors we discuss multiple issues regarding cardiac progenitor cell-based tissue engineering strategies, and, conversely, about the possible antifibrotic mechanisms induced by cell therapy. For more on this fascinating subject, see STEM CELLS Translational Medicine.
In Vitro Biology of Human Hematopoietic Cells
The in vitro expansion of human hematopoietic stem (HSCs) and progenitor (HPCs) cells permits their application in a range of experimental strategies, but at what cost? Researchers from the lab of Hector Mayani (National Medical Center, IMSS, San Pablo Tepetlapa, Coyoacan, Mexico) have now established that in vitro culture promoted significant differences, both in functional and genetic terms, when compared to non-cultured cells. Dircio‐Maldonado et al. discovered that in vitro HSCs displayed a deficient content of long‐term culture‐initiating cells, and a marked differentiation bias toward the myeloid lineage, while both HSCs and HPCs demonstrated a limited expansion potential. For all the fine print, head over to STEM CELLS Translational Medicine now!
A Five-Year Study of PuCeT for AICLI
A new STEM CELLS Translational Medicine study brings us the results of a purified CD34+ cell transplantation (PuCeT) therapy for angiitis‐induced critical limb ischemia (AICLI) patients. The five-year-long trial, carried out by researchers from the lab of Zhihui Dong and Weiguo Fu (Fudan University, Shanghai, China), found long‐term efficacy and durability of autologous transplantation of purified CD34+ cells including achievement of ideal limb salvage, recovery of labor competence, and improved quality of life. Great news!
That’s a wrap for now! Please feel free to leave a comment and discuss the papers covered here on the Stem Cells Buzz. Happy reading!